Alembic Pharmaceuticals Ltd
Please find attached Press Release on Unaudited Financial Results for the quarter ended 30th June, 2026.
RESULTS
▲ Positive Development
LOW RISK
📅 Filed on BSE: 04 Aug 2026, 02:20 PM IST · BSE ID: 16060660-33c2-4caf-9cf4-3de9a5abfb95
View Original BSE Filing (PDF)
💡
In Simple Terms
Alembic Pharmaceuticals announced its quarterly financial results, showing higher sales and profit compared to last year.
🤖 AI Summary
- Alembic Pharmaceuticals reported consolidated revenue from operations of Rs. 2150 Cr for Q1 FY27, a 26% YoY increase.
- Profit After Tax (PAT) for Q1 FY27 was Rs. 173 Cr, reflecting a 12% YoY growth.
- EBITDA pre R&D increased to Rs. 523 Cr, with the margin recorded at 24% for the quarter.
- The US Formulation business achieved Rs. 778 Cr, growing 49%, and India Branded Business grew 7% to Rs. 642 Cr.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Revenue from operations (Q1 FY27)
Rs. 2150 Cr
26%
Profit After Tax (Q1 FY27)
Rs. 173 Cr
12%
EBITDA pre R&D (Q1 FY27)
Rs. 523 Cr
EBITDA margin pre R&D (Q1 FY27)
24%
India Branded Business (Q1 FY27)
Rs. 642 Cr
7%
US Formulation (Q1 FY27)
Rs. 778 Cr
49%
Ex-US Generics (Q1 FY27)
Rs. 383 Cr
17%
API business (Q1 FY27)
Rs. 346 Cr
33%
🏢 How This Affects the Company
Consolidated revenue growth of 26% and strong performance in the US Formulation market (up 49%) indicate expansion in key international segments. The introduction of 3 new products in India and 7 launches in the US market contributes to product portfolio strengthening.
Profit After Tax increased by 12% YoY to Rs. 173 Cr, and EBITDA pre R&D rose to Rs. 523 Cr, maintaining a 24% margin, reflecting improved operational profitability.
Growth across India Branded Business, US Formulation, Ex-US Generics, and API segments suggests effective execution across diverse operational areas. The 10 ANDA approvals signify progress in regulatory submissions for new products.
👥 What This Means For Shareholders
✅
Action Required
No action required from shareholders based on this financial results disclosure.
👤
Who Is Affected
All shareholders are affected by the company's financial performance, which showed consolidated revenue growth of 26% and PAT growth of 12% for Q1 FY27.
🔍
Management Signal
Management commentary emphasizes broad-based growth, healthy volume expansion, successful new product launches, and focus on strengthening the product portfolio and pipeline.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Investor call on August 4, 2026, for management insights on Q1 FY27.
Q2 FY27 financial results to assess sustained growth across segments.
Updates on new product launches and ANDA approvals in key markets.
LOW RISK
The filing reports strong growth in revenue and profit, indicating a stable financial position.
💡 Investor Takeaway
Alembic Pharmaceuticals reported Q1 FY27 consolidated revenue of Rs. 2150 Cr, up 26% YoY from Rs. 1711 Cr in Q1 FY26. Profit After Tax increased 12% YoY to Rs. 173 Cr. US Formulation business grew 49% to Rs. 778 Cr.
⚖️ Strengths & Concerns
✅ Positives
- Consolidated Revenue from operations increased by 26% YoY to Rs. 2150 Cr, demonstrating broad-based business growth across segments.
- US Formulation business grew 49% to Rs. 778 Cr, driven by 7 new product launches, indicating strong international market penetration.
📅 Company Track Record
Alembic Pharmaceuticals previously informed BSE on August 4, 2026, about its Q1 FY27 consolidated revenue of Rs. 2,149.77 Crores and profit of Rs. 173.07 Crores. A board meeting was held on August 4, 2026, to approve these unaudited financial results.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What was Alembic Pharmaceuticals' consolidated revenue in Q1 FY27?
Alembic Pharmaceuticals reported consolidated revenue from operations of Rs. 2150 Cr in Q1 FY27, a 26% increase compared to Q1 FY26.
What was Alembic Pharmaceuticals' Profit After Tax in Q1 FY27?
The Profit After Tax for Alembic Pharmaceuticals in Q1 FY27 was Rs. 173 Cr, representing a 12% increase from the previous year.
How did Alembic Pharmaceuticals' US Formulation business perform in Q1 FY27?
The US Formulation business of Alembic Pharmaceuticals grew by 49% in Q1 FY27, reaching a revenue of Rs. 778 Cr.
What was the growth rate for Alembic Pharmaceuticals' India Branded Business in Q1 FY27?
Alembic Pharmaceuticals' India Branded Business delivered 7% YoY growth in Q1 FY27, achieving Rs. 642 Cr in revenue.
Questions based on this BSE filing only. For information purposes.